GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Capital Expenditure

Hinova Pharmaceuticals (SHSE:688302) Capital Expenditure : ¥-89.33 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Hinova Pharmaceuticals's cash flow for capital expenditures for the three months ended in Mar. 2025 was ¥-26.66 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-89.33 Mil.

Hinova Pharmaceuticals Capital Expenditure Historical Data

The historical data trend for Hinova Pharmaceuticals's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals Capital Expenditure Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial -2.50 -19.77 -69.21 -99.18 -89.55

Hinova Pharmaceuticals Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.89 -51.87 -31.18 20.38 -26.66

Hinova Pharmaceuticals Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-89.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » Capital Expenditure
Comparable Companies
SZSE:300147 SHSE:688315 SHSE:688197 SHSE:688488 SHSE:603566 BJSE:833575 SHSE:688046 SZSE:300871 BJSE:839273 SHSE:688075 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Website
http://www.hinovapharma.com
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines